Patents Assigned to Institut National de la Santé et de la Recherche Médicale
-
Patent number: 11903382Abstract: Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and/or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.Type: GrantFiled: January 11, 2023Date of Patent: February 20, 2024Assignees: UNIVERSITE DE TECHNOLOGIE DE COMPIEGNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARISInventors: Cécile Legallais, Patrick Paullier, Olivier Scatton, Eric Savier
-
Patent number: 11905253Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.Type: GrantFiled: April 19, 2019Date of Patent: February 20, 2024Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE RENNES 1, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, INSTITUT BERGONIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE BORDEAUXInventors: Pierre Vacher, Patrick Legembre, Mickael Jean, Patrick Blanco, Pierre Van De Weghe
-
Publication number: 20240053345Abstract: The present invention relates to a polypeptide X1X2-RK-X3X4-KK-X5X6X7X8X9X10-KR-X11X12 SEQ ID NO: 1 able to bind selectively to cells expressing proteoglycans comprising glycosaminoglycans as heparin or heparan sulfate. The linkage of said polypeptide to an internalization peptide enables the polypeptide to be internalized. The present invention further relates to a conjugated polypeptide comprising said polypeptide and a biomarker, to a cell penetrating polypeptide comprising said polypeptide, optionally a linker and a cell internalization peptide and a chimeric polypeptide comprising said cell penetrating polypeptide and one or more biological cargos.Type: ApplicationFiled: December 17, 2020Publication date: February 15, 2024Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCEInventors: Sandrine Sagan, Alain Joliot, Astrid Walrant, Ludovic Carlier, Sébastien Cardon
-
Patent number: 11896649Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.Type: GrantFiled: September 27, 2022Date of Patent: February 13, 2024Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
-
Publication number: 20240041423Abstract: A device tracking system for monitoring a target body structure and localizing a device inside the target body structure. The device tracking system includes: a control unit, a device having one steering element to be handled outside the target body structure and one steerable element to be introduced inside the target body structure, one probe to be removably secured to the patient, and one tracker to be secured to the steerable element. The control unit stores one ultrasound image of the target body structure. The probe and the tracker communicate, and the control unit is able to localize, in real time, the steerable element. The control unit displays, the stored ultrasound image and displays, in real time, the localisation of the at steerable element on the at least one ultrasound image.Type: ApplicationFiled: December 10, 2021Publication date: February 8, 2024Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Antoine COUDERT, Olivier COUTURE, Vincent HINGOT
-
Publication number: 20240034791Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.Type: ApplicationFiled: March 31, 2022Publication date: February 1, 2024Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
-
Publication number: 20240033366Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.Type: ApplicationFiled: December 2, 2021Publication date: February 1, 2024Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L’ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), UNIVERSITE PARIS CITE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS)Inventors: Ludger JOHANNES, Anne BILLET, Jonathan ULMER, Denis SERVENT, Gilles MOURIER, Pascal KESSLER, Eric TARTOUR
-
Patent number: 11883398Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.Type: GrantFiled: December 15, 2021Date of Patent: January 30, 2024Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Rosa Barreira Da Silva, Matthew Albert
-
Patent number: 11879038Abstract: The present invention relates to a polymer foam, said polymer foam comprising pores forming an open-cell polymer foam, said polymer foam comprising a supramolecular gel inside pores, and said polymer foam comprising at least one enzyme. The present invention relates to a supramolecular gel; its preparation and its applications, notably in chemical synthesis and kinetic resolution, in particular of organic compounds. The present invention also relates to flow chemistry.Type: GrantFiled: September 9, 2020Date of Patent: January 23, 2024Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Loïc Jierry, Christophe Serra, Pierre Schaaf, Jennifer Rodon Fores, Fouzia Boulmedais
-
Publication number: 20240010739Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.Type: ApplicationFiled: November 10, 2021Publication date: January 11, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
-
Publication number: 20240008951Abstract: A computer-implemented method and a system for providing anatomical landmarks of a subject's body part using a set of measures previously acquired by an ultrasound device including at least one fiducial marker and an imaging sensor. Also, a non-transitory computer readable medium including instructions which, when the program is executed by a computer, cause the computer to carry out the method.Type: ApplicationFiled: November 17, 2021Publication date: January 11, 2024Applicants: CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE BREST, UNIVERSITÉ DE BRETAGNE OCCIDENTALE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Guillaume DARDENNE, Hoel LETISSIER, Jérôme OGOR, Eric STINDEL
-
Patent number: 11865185Abstract: The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.Type: GrantFiled: June 9, 2017Date of Patent: January 9, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), NANTES UNIVERSITE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTESInventors: Mathieu Mevel, David Deniaud, Eduard Ayuso
-
Patent number: 11865189Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.Type: GrantFiled: December 17, 2015Date of Patent: January 9, 2024Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Thierry Leveillard, Christo Kole, Jose-Alain Sahel
-
Patent number: 11866484Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: GrantFiled: March 3, 2021Date of Patent: January 9, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Publication number: 20240002521Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERAAN BIOTECHNOLOGY, UNIVERSITE D'AIX MARSEILLE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
-
Publication number: 20240002522Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERANN BIOTECHNOLOGY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE, UNIVERSITE PARIS CITE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jerome GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
-
Patent number: 11857532Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.Type: GrantFiled: December 27, 2019Date of Patent: January 2, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)Inventors: Anne Agnès Rotig, Arnold Munnich, Floriane Petit
-
Patent number: 11852704Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.Type: GrantFiled: March 17, 2022Date of Patent: December 26, 2023Assignees: Siemens Healthcare GmbH, Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), King's College London, Department of Health and Human Services, UNIV PARIS XIII PARIS-NORD VILLETANEUSE, Universite de ParisInventors: Giacomo Annio, Verena Muller-Reinwald, Ralph Sinkus, Omar Darwish, Wilfried Schnell, Tamara Elisabeth Falkner, Ahmed M. Gharib
-
Publication number: 20230407264Abstract: The present invention relates to a population of cells comprising hepatic stem-like cells and therapeutic use thereof, for the treatment and the prevention of fulminant liver disorders. The hepatic stem-like cells according to the invention may be safely and reproducibly generated from pluripotent stem cells. In addition, although the hepatic stem-like cells according to the invention do not display the phenotype of physiologically mature hepatic cells, as they are lacking the albumin expression marker (ALB?), they may still be transplanted in a diseased liver with acute failure, rescue the diseased liver and promote liver regeneration. Moreover, various protocols of preparation of hepatic stem-like cells according to the invention may be implemented, all resulting in high quality and high yield of production. Finally, the hepatic stem-like cells according to the invention may be cryopreserved and may also be prepared as spheroid particles.Type: ApplicationFiled: March 15, 2021Publication date: December 21, 2023Applicants: Goliver Therapeutics, Nantes Universite, Institut National de la Santé et de la Recherche MédicaleInventors: Tuan Huy Nguyen, Angélique Fourrier, Raphaël Rispal, Frédéric Delbos
-
Publication number: 20230393152Abstract: An identification of novel combinations of specific metabolites for neurodegenerative diseases for use as biomarkers in the early diagnosis of neurodegenerative diseases.Type: ApplicationFiled: November 18, 2021Publication date: December 7, 2023Applicants: UNIVERSITE GRENOBLE ALPES, INSERM - Institut National de la Santé et de la Recherche MédicaleInventors: Sabrina BOULET, Florence FAUVELLE, David MALLET